🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "major milestone" in the fight against increasingly resistant strains of the infection, according to health experts.

An International Challenge

The sexually transmitted infection are on the rise globally, with estimates suggesting more than 82 million new cases annually. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

One new antibiotic, also known as Nuzolvence, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts hope that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization signifies a significant shift in the therapy of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

Based on results detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which combines a dual-drug approach. The trial involved nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Doctors treating patients have expressed hope. The availability of a single-dose, oral treatment such as this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as essential to reduce the burden of the illness for patients and to prevent the spread of untreatable gonorrhoea worldwide.